New technologies are needed to help diagnose anxiety disorders. EVestG has facilitated the identification of numerous possible biomarkers of several psychiatric disorders. Some EVestG features seem to be caused by differences in low-frequency modulation that is consistent (both in frequency and behaviour) with the hippocampal rhythm (theta), which is known to play a role in anxiety. Critically, there is ample support in the literature for an anatomical and functional basis for the modulation of vestibular signals via theta. If anxiety could be measured continuously, perhaps throughout a patient's day, or throughout a task, it might be able to confirm an anxiety disorder. However, current techniques for measuring theta are highly invasive, performed rarely, and only in epilepsy patients. EVestG technology, however, is non-invasive, and could potentially record anxiety levels in any subject for extended periods of time. The proposed study will attempt to identify hippocampal theta in vestibular signals in healthy participants through a double-blind administration of two different drugs that are dissimilar both pharmacologically and in acute clinical effects but which are known to reduce the theta rhythm.

开始日期2023-10-16

申办/合作机构

University of Manitoba

NCT03360123 / CompletedN/AIIT

Oral Anxiolysis for the Older Pediatric Patient-Which Medication is Preferred?

This study will evaluate the perceptions of the effects of two anxiolytic medications commonly used during dental treatment in patients weighing 40 kilograms or more.

开始日期2018-01-26

申办/合作机构

University of Pittsburgh

NCT03246724 / Completed临床4期IIT

A Single-center, Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing Oral Sedation to Intravenous Sedation for Ocular Procedures.

The purpose of this study is to evaluate patient satisfaction after eye surgery when given a capsule compared to an intravenous (IV) dose of sedation (calming medication).
Each subject will be given a capsule and an IV in the hospital before their procedure starts, however they will not know which one is the sedation route. Each subject will have their planned surgical procedure as previously discussed with their doctor. After the procedure is completed, the doctors will complete satisfaction surveys. The subject will also complete a satisfaction survey during their regularly scheduled visit the day after surgery. Once the subject completes this survey, their study participation will be complete.
The hypothesis is that there will be no difference in patient satisfaction when given a capsule in comparison to IV sedation. If the results of the study support this hypothesis, a capsule could be used in place of IV sedation. By using a capsule for ocular procedures, both patients and the medical practice would benefit: patient would be able to eat before their procedure, patient costs would be decreased, hospital costs would be reduced, and some of these procedures would be given the option to move to a procedure room (freeing up operating room time for other departments).

开始日期2017-10-16

申办/合作机构

Boston Medical Center

100 项与三唑仑相关的临床结果

登录后查看更多信息

100 项与三唑仑相关的转化医学

登录后查看更多信息

100 项与三唑仑相关的专利（医药）

登录后查看更多信息

1,568

项与三唑仑相关的文献（医药）

2024-09-01·Journal of vitreoretinal diseases

Pars Plana Vitrectomy Without Intravenous Anesthesia: Technique, Safety, and Outcomes

Article

作者: Tien, Karena X. ; Romo, Erica ; Adam, Murtaza K.

Introduction: To describe the technique, safety profile, and outcomes of performing pars plana vitrectomy (PPV) without intravenous (IV) anesthesia. Methods: This retrospective single-surgeon study comprised patients who had PPV without IV sedation between September 2018 and April 2022. Patients elected to undergo PPV without sedation or with oral sedation via sublingual triazolam administered 30 minutes preoperatively. Sub-Tenon bupivacaine and lidocaine were administered at the initiation of each case. A circulating nurse monitored patient vitals and electrocardiogram tracings without anesthesiologist support. Adverse events (AEs), visual acuity (VA), supplemental block administration, and reoperation rates were documented. Results: A total of 357 PPVs in 319 patients (mean age 68.75 ± 11.17 years [SD]; range, 36.82-98.57) were performed for surgical indications including vitreous floaters, intraocular lens or cataract surgery complications, retinal detachment, vitreous hemorrhage, and epiretinal membrane. Twenty-three cases were performed without sedation, and 334 were performed with oral sedation. For eyes with a follow-up longer than 1 month (n = 324), the preoperative VA of 0.68 ± 0.77 logMAR improved to 0.31 ± 0.46 logMAR postoperatively ( P < .01). No intraoperative complications, systemic AEs, need to cease surgery prematurely, or conversion to IV sedation occurred. Five eyes (1.77%) required intraoperative supplemental sub-Tenon block administration, and 95% of patients who had a reoperation (n = 10) or fellow-eye surgery (n = 28) requested the same method of anesthesia without IV sedation. Conclusions: Vitreoretinal surgery with a sub-Tenon block and oral sedation can be safely performed without the support of an anesthesiologist. Additional trials are needed to further quantify patient comfort, surgeon experience, and complication rates.

2024-06-01·Pharmacology research & perspectives

Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: Alterations of gene expression, microsomal activity, and pharmacokinetics

Article

作者: Minegishi, Genki ; Kazuki, Yasuhiro ; Kobayashi, Yuka ; Kobayashi, Kaoru ; Fujikura, Mayu ; Sano, Ayane

Abstract:

Human cytochrome P450 3A4 (CYP3A4) is a drug‐metabolizing enzyme that is abundantly expressed in the liver and intestine. It is an important issue whether compounds of interest affect the expression of CYP3A4 because more than 30% of commercially available drugs are metabolized by CYP3A4. In this study, we examined the effects of cholesterol and cholic acid on the expression level and activity of CYP3A4 in hCYP3A mice that have a human CYP3A gene cluster and show human‐like regulation of the coding genes. A normal diet (ND, CE‐2), CE‐2 with 1% cholesterol and 0.5% cholic acid (HCD) or CE‐2 with 0.5% cholic acid was given to the mice. The plasma concentrations of cholesterol, cholic acid and its metabolites in HCD mice were higher than those in ND mice. In this condition, the expression levels of hepatic CYP3A4 and the hydroxylation activities of triazolam, a typical CYP3A4 substrate, in liver microsomes of HCD mice were higher than those in liver microsomes of ND mice. Furthermore, plasma concentrations of triazolam in HCD mice were lower than those in ND mice. In conclusion, our study suggested that hepatic CYP3A4 expression and activity are influenced by the combination of cholesterol and cholic acid in vivo.

2024-06-01·Neuropsychopharmacology reports

Comparison of patients with benzodiazepine receptor agonist‐related psychiatric disorders and over‐the‐counter drug‐related psychiatric disorders before and after the COVID‐19 pandemic: Changes in psychosocial characteristics and types of abused drugs

Article

作者: Usami, Takashi ; Shimane, Takuya ; Matsumoto, Toshihiko ; Okita, Kyoji

Abstract:

Aim:

To investigate changes in the clinical characteristics of patients who abused benzodiazepine receptor agonists (BZRA) or over‐the‐counter (OTC) drugs before and after COVID‐19 based on the 2018 and 2022 data of the “Nationwide Psychiatric Hospital (NPH) Survey on Drug‐related Psychiatric Disorders.”

Method:

A total of 446 and 155 cases, and 435 and 273 cases, who mainly abused BZRAs or OTC drugs, respectively, were extracted from the database of the two NPH Surveys. Demographic variables, education, employment, criminal record, drug use during the previous year, psychiatric diagnosis, and types of abused drugs were compared between 2018 and 2022.

Result:

A comparison of BZRA abusers revealed a decreased number of users during the previous year and an increase in the comorbidity rate of other disorders (F3 and F4 in ICD‐10) in 2022. Etizolam, flunitrazepam, triazolam, and zolpidem were used most in both years, with an increase in zolpidem and a decrease in triazolam in 2022. A comparison of OTC drug abusers revealed a higher proportion of women and young patients in 2022. An increase in the comorbidity rate of F3 and F9 and a significant increase in the use of dextromethorphan products were observed in 2022, although codeine products were in the majority in both years.

Conclusion:

By comparing NPH Surveys before and after the COVID‐19 pandemic, both BZRA abusers and OTC drug abusers present complex pathologies, requiring tailor‐made treatment. The younger OTC drug abusers were particularly evident among women, and the abuse of dextromethorphan‐containing OTC drugs has increased alarmingly.

项与三唑仑相关的新闻（医药）

2024-07-02

·drugs

Use of 'Benzo' Sedatives Like Valium, Xanax Won't Raise Dementia Risk: Study

TUESDAY, July 2, 2024 -- Benzodiazepines do not appear to increase dementia risk, but could have subtle long-term effects on brain structure, a new study reports. Researchers found no link between use of the sedative drug and a higher risk of dementia in a group of more than 5,400 adults in the Netherlands, according to findings published July 2 in the journal BMC Medicine . That runs counter to two previous meta-analyses reporting increased dementia risk with benzodiazepine use, researchers noted. However, brain MRI scans taken of more than 4,800 participants revealed that benzodiazepine use is associated with accelerated shrinking of some brain regions, results show. The findings “support current guidelines cautioning against long-term benzodiazepine prescription,” concluded the research team led by Dr. Frank Wolters , a senior scientist of epidemiology and radiology and nuclear medicine at Erasmus Medical Center in the Netherlands. “Further research is needed to investigate the potential effects of benzodiazepine use on brain health,” the team adds. Benzodiazepines promote the release of a neurotransmitter that makes the nervous system less active, the Cleveland Clinic says. Different types are used as sedatives or to treat anxiety , insomnia and seizures. Analysis of medical records between 2005 and 2020 and pharmacy records between 1991 and 2008 revealed no association between benzodiazepines and increased risk of dementia, regardless of the total quantity of sedatives people took over time. The team also found no link between dementia risk and specific types of benzodiazepines or the time it took for dosages to wear off. However, benzodiazepine use was associated with an accelerated reduction in the volume of the hippocampus and amygdala, which are brain regions involved in memory and mood regulation. Certain types of benzodiazepines also were associated with changes in the size of white matter, which transmits nerve signals between brain regions, researchers said. Anxiolytic benzodiazepines prescribed for anxiety caused less shrinkage of white matter, results show. These include alprazolam (Xanax), clonazepam (Klonopin), clorazepate (Tranxene) and lorazepam (Ativan, Loreev), according to the Cleveland Clinic. On the other hand, sedative-hypnotic benzodiazepines prescribed for sleep problems caused a quicker reduction in white matter volume. These include temazepam (Restoril), triazolam (Halcion) and quazepam (Doral), the Cleveland Clinic says. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-06-24

·GlobeNewswire-Health Care

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial. AKYNZEO injection (Ready-to-Use) is a new method of administration and contains the same formulation as the prior AKYNZEO Injection (To-be-Diluted). The features of the new ready-to-use presentation of AKYNZEO injection include: No reconstitution or dilution required; infuse directly from the vial using a built-in hanging strapNo refrigeration required at any point during distribution, storage, or preparationAccessible via automated dispensing machine, allowing the product to be stored and available near the location of patient care AKYNZEO injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin. It can be administered simultaneously with intravenous dexamethasone sodium phosphate. Dr. Melanie Rolli, Helsinn Group CEO, commented: “As a pioneer in cancer supportive care, Helsinn continues to be unwavering in our pursuit to help patients and clinicians in cancer care. We are very pleased to launch the new AKYNZEO Ready-to-Use vial, building on our legacy of innovation.” Ordering information Clinicians wishing to order the new vial should contact their GPO or distributor. The National Drug Code (NDC) number for AKYNZEO injection vial with hanger (Ready-to-Use) is 69639-106-01 and the J Code is J1454 (Injection, fosnetupitant 235 mg and palonosetron 0.25 mg); billing unit (single dose vial [SDV]). About AKYNZEO® AKYNZEO is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. A single dose of AKYNZEO given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days. INDICATION AKYNZEO (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use AKYNZEO injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. IMPORTANT SAFETY INFORMATION Warnings and Precautions Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs. Adverse Reactions Most common adverse reactions (≥3%) for AKYNZEO capsules are headache, asthenia, dyspepsia, fatigue, constipation and erythema. The safety profile of AKYNZEO injection was generally similar to AKYNZEO capsules. Drug Interactions Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days Dexamethasone doses should be reduced when given with AKYNZEO. A more than two- fold increase in the systemic exposure of dexamethasone was observed 4 days after a single infusion of fosnetupitant.Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased. Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO. Use in Specific Populations Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease.Advise women of potential risk to fetus; limited data are available; may cause fetal harm. For more information about AKYNZEO® please see the full US Prescribing Information. About Helsinn Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and an extensive network of long-standing trusted partners enabling a commercial presence in more than 90 countries. Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision. To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X. For more information: Helsinn Group Media Contact:Sabrina PerucchiGroup Communication ManagerLugano, Switzerland Tel: +41 (0) 91 985 21 21 Email: Info-hhc@helsinn.com

上市批准临床结果

2024-01-03

·CPHI制药在线

失眠药物治疗研究进展

关注并星标CPHI制药在线睡眠障碍是指睡眠质量异常或睡眠时发生某些临床症状，如睡眠减少或睡眠过多、睡眠相关运动障碍等，后者包括睡眠行走、睡眠惊恐、不宁腿综合征等。其中最主要最常见的是失眠障碍，以持续睡眠时间过短、早醒以及入睡困难为最主要的3个症状。失眠治疗有躯体治疗(包括药物治疗、物理治疗等) 、心理治疗或者心理治疗联合躯体治疗的综合治疗等。虽然美国内科医师学会将认知行为疗法确定为失眠的一线治疗方法。但由于认知行为疗法存在费用高、咨询时间长、缺乏训练有素的提供者及不能立竿见影等弊端，难以在临床开展。因此，药物治疗依然广泛应用于是失眠治疗。目前推荐在临床常用的治疗失眠药物包括苯二氮䓬受体激动剂、褪黑素及褪黑素受体激动剂、食欲素受体拮抗剂、组胺拮抗剂及抗焦虑、抗抑郁类药物。对单纯失眠患者，一般首选非苯二氮䓬类药物或褪黑素受体激动剂单药治疗，当单药治疗效果不佳时考虑联合不同作用机制的镇静催眠药治疗；对合并情绪障碍患者，需根据症状选择苯二氮䓬类药物或联合具有镇静作用的抗抑郁药、抗精神病药物治疗。 1、苯二氮䓬受体激动剂苯二氮䓬受体激动剂（benzodiazepine receptor agonists，BzRAs）作为临床上最常用于治疗失眠的药物，可分为苯二氮䓬类药物（benzodiazepine drugs，BZDs）与非苯二氮类药物（nonbenzodiazepine drugs，NBZDs）。临床常见用于失眠治疗的BZDs有阿普唑仑、艾司唑仑、劳拉西泮、氯硝西泮等，主要适用于入睡困难和睡眠维持障碍的成年患者，尤其适用于伴有焦虑症的失眠患者。BZDs 通过非选择性结合苯二氮䓬受体，增加γ- 氨基丁酸（gamma aminobutyric acid，GABA）受体的亲和力，促进氯离子内流，导致苯二氮䓬受体所在神经元出现超极化，起到镇静催眠、抗焦虑和肌肉松弛等药理作用。BZDs 可以缩短睡眠潜伏期，减少夜间觉醒，增加总睡眠时间，但深度睡眠时间减少，患者服用后虽然觉得入睡改善、睡眠时间延长，但睡眠质量仍较低。BZDs可能会导致日间思睡、头晕、乏力和认知功能下降，老年患者还可能增加跌倒、骨折的风险。长期使用BZDs 的患者可能形成心理和躯体依赖，且部分患者在停药后出现严重的戒断症状，出现反跳性失眠和焦虑情绪加重，因此长期服用BZDs 的患者需缓慢撤药。美国医师协会在失眠药物治疗指南列出批准治疗失眠的BZDs 有艾司唑仑、氟西泮、夸西泮、替马西泮和三唑仑。 NBZDs通过选择性结合苯二氮䓬受体，抑制睡眠中枢产生镇静催眠作用，但一般不具有抗焦虑作用。临床上常见的NBZDs 有唑吡坦、扎来普隆、佐匹克隆和右佐匹克隆， NBZDs的半衰期较短，白天残留镇静作用少见，尤其唑吡坦和扎来普隆对改善入睡困难效果满意，但对睡眠维持作用不大，佐匹克隆和右佐匹克隆半衰期稍长，对入睡困难和睡眠维持障碍均有作用。 2、褪黑素和褪黑素受体激动剂褪黑素作为重要的生理性睡眠调节因子，其昼夜节律的变化与睡眠节律密切相关。褪黑素由松果体分泌，呈昼少夜多的节律，凌晨2～3点分泌达到高峰，主要作用于下丘脑的褪黑素受体，调节睡眠-觉醒周期。研究发现，外源性褪黑素可能对缩短睡眠潜伏期、增加总睡眠时间有效，但临床观察发现大多数患者对于失眠治疗效果不满意，可能更适合睡眠节律失调的失眠患者。褪黑素主要通过2个高亲和力膜受体MT1和MT2发挥其生理作用。视交叉上核在光-暗循环周期的调控下，通过激活 MT1 和(或MT2) 受体反馈回细胞核以调节睡眠和昼夜节律周期。雷美替胺是首个获准上市的选择性褪黑素受体激动剂，已被 FDA 批准用于治疗失眠，主要改善入睡困难，但在国内未上市。该药物可缩短睡眠潜伏期，增加总睡眠时间，不良反应有头晕、思睡、疲劳、头痛、恶心，加重原发性抑郁症患者的抑郁症状和自杀观念等。阿戈美拉汀是国内仅有的一种褪黑素受体激动剂，具有激动褪黑素受体（MT1/MT2）和5-HT2C受体拮抗的双重机制，研究发现，阿戈美拉汀可改善睡眠维持障碍，增加深睡眠和总睡眠时间、减少入睡后总觉醒时间、提高睡眠效率，因此对有入睡困难患者需联合苯二氮䓬受体激动剂效果更佳。由于该药同时是抗抑郁药，对失眠伴轻中度焦虑抑郁患者可起到改善睡眠和情绪的双重作用，但需注意使用该药物需监测肝功能，对肝功能损害者禁止使用。 3、食欲素受体拮抗剂食欲素( Orexins，OX) 主要由下丘脑外侧、背侧和弯窿区分泌，又称下丘脑分泌素，被称为下丘脑的"觉醒启动区"，可促进食欲且具有促醒作用，对维持长期觉醒很重要，食欲素的生成减少将导致发作性嗜睡和不规则快速眼动睡眠。研究表明，大鼠脑脊髓液内和下丘脑外侧、丘脑内侧的细胞外食欲素A水平呈显著的日节律变化，在黑暗期慢慢上升，在光照期慢慢下降。说明食欲素可调节睡眠-觉醒周期，正常睡眠的控制有赖于下丘脑的食欲素的调节。食欲素能神经元投射最密集的地方是蓝斑核，食欲素A可以通过激活蓝斑去甲肾上腺素能细胞促进觉醒，单胺能和胆碱能神经核是食欲素受体富集区，食欲素神经元在睡眠时保持静息，在即将觉醒前开始放电，在觉醒和睡眠剥夺时活跃。睡眠剥夺通过突触前和突触后机制可以改变食欲素神经元的兴奋性，食欲素可促使前额皮层神经元放电，并通过激活组胺能、去甲肾上腺素能和血清素促进觉醒。食欲素受体拮抗剂只选择性地阻断食欲素受体，食欲素的拮抗剂可改善失眠，提高睡眠质量，没有BZDs类药物的不良反应，却比传统安眠药有更强的药理活性。双食欲素受体拮抗剂( Suvorexant、Almorexant 等) 可通过促进REM睡眠增加总睡眠时间，具有较好的临床疗效和耐受性，已获得FDA批准用于治疗失眠。 4、组胺拮抗剂组胺是一种促进清醒的神经递质，在中枢神经系统中产生于下丘脑的结节乳头核中。因此拮抗组胺受体可促进睡眠。在组胺的4个受体中，H1受体是控制睡眠的关键靶点。有证据表明，敲除 H1 受体的小鼠，在给予 H1 受体拮抗剂多塞平和苯海拉明能够增加 NREM时间和发作次数。而酮替芬则通过增加δ波功率来降低REM 并增加 NREM。从以上数据可推测，组胺拮抗剂对睡眠的影响主要作用于NREM 阶段。但服用抗组胺药可引发抗胆碱能作用，包括发热、脓毒症、视力模糊、口干、便秘、尿潴留、心动过速、肌张力障碍和精神错乱等不良反应。组胺拮抗剂目前对于治疗人类失眠的数据较少，其中多塞平是组胺拮抗剂中用来控制失眠最常用的药物，其能延长 NREM 但减少 REM，但易造成恶心、呼吸道感染等不良反应。 5、抗焦虑、抗抑郁类药物抗焦虑、抗抑郁类药物主要是 5-羟色胺受体( 5-HT1A ) 受体部分激动剂。主要代表有丁螺环酮和坦度螺酮，属于抗焦虑药，由于其对5-HT1A具有良好的亲和力，能够激活突触前5-HT1A受体抑制神经元放电，减少 5-HT1A 的合成与释放，主要用于治疗各种焦虑症以及各种伴发的焦虑症。在治疗焦虑性失眠上，临床使用坦度螺酮较多。该类药物的优点在于镇静作用轻，对认知功能影响较小，无蓄积性，相较于BZDs类药物产生的不良反应更少。但起效相对较慢，为2～4 周。临床研究表明在镇静催眠药上加用坦度螺酮对伴有焦虑症状的失眠患者有更好的治疗作用，联合用药的症状改善效果更好。大部分失眠患者治疗效果不佳的原因可能是忽略了焦虑、抑郁等情感状态的障碍，虽然并无直接证据表明抗抑郁、抗焦虑药物能直接改善失眠，但在由心理、精神因素造成的睡眠问题上，能够起到有效的改善作用，因此在治疗时应充分把握患者病情，必要时应同时考虑抗焦虑、抗抑郁治疗。相关阅读：《失眠障碍新药获批上市，更多创新药很快就到！》参考资料 [1]冯庭宇,许晓伍.失眠症的药物治疗进展[J].世界睡眠医学杂志,2023,10(03):691-696. [2]胡金,韦姗姗,姜海洲等.失眠的药物治疗研究进展[J].中国中药杂志,2023,48(19):5122-5130. [3]沈阳阳,周俊英.失眠药物治疗及进展[J].中国临床医生杂志,2023,51(12):1394-1397. 作者简介：小米虫，药品质量研究工作者，长期致力于药品质量研究及药品分析方法验证工作，现就职于国内某大型药物研发公司，从事药品检验分析及分析方法验证。智药研习社1月直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

临床结果

100 项与三唑仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00387	三唑仑	N05CD05	DB00897

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	日本	Pfizer Japan, Inc.	1982-12-15
入睡和睡眠障碍	美国	Pfizer Inc.	1982-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03246724 (CTgov)	临床4期	镇静	327	Sodium chloride 0.9%+Microcrystalline Cellulose+Triazolam+Midazolam (Cataract Procedures)	繭窪遞鹽遞網繭憲網繭(選壓鹽衊蓋顧餘築網艱) = 夢衊夢餘蓋齋醖餘積鏇鏇積選夢齋繭鹹餘廠窪 (襯構獵蓋積鏇繭蓋鬱鹹, 選廠壓鹽淵鏇壓製鏇遞 ~ 蓋衊窪膚觸窪製膚遞簾) 更多	-	2020-08-19
				Sodium chloride 0.9%+Microcrystalline Cellulose+Triazolam+Midazolam (Retina Procedures)	繭窪遞鹽遞網繭憲網繭(選壓鹽衊蓋顧餘築網艱) = 憲鑰餘觸餘齋遞窪廠積鏇積選夢齋繭鹹餘廠窪 (襯構獵蓋積鏇繭蓋鬱鹹, 鏇齋顧糧憲餘餘構醖獵 ~ 醖選鹹廠遞艱衊選齋獵) 更多
WSC2017	N/A	入睡和睡眠障碍	36	Sleep medication (+)	積構積網願衊製鏇顧鏇(鬱鹹夢餘鬱廠膚窪衊餘) = 製襯願鹹鏇衊製網淵遞憲蓋顧襯鹹鏇醖壓構顧 (襯鹽簾鏇構夢蓋範衊醖, 8.7) 更多	不佳	2017-10-07
				Sleep medication (-)	積構積網願衊製鏇顧鏇(鬱鹹夢餘鬱廠膚窪衊餘) = 餘襯壓構繭淵餘廠製壓憲蓋顧襯鹹鏇醖壓構顧 (襯鹽簾鏇構夢蓋範衊醖, 8.4) 更多
SFN2010	N/A	-	-	Triazolam	糧憲築選積夢襯齋構憲(膚膚壓齋鬱製艱鹹膚艱) = 夢繭簾淵衊艱範鹹鹹窪廠鹽餘餘構築鑰遞齋齋 (鑰艱鹹繭廠餘醖艱膚築, 0.00014 ~ 0.0012) 更多	-	2010-11-13
				Pregnanolone	糧憲築選積夢襯齋構憲(膚膚壓齋鬱製艱鹹膚艱) = 艱鹽糧遞醖築膚憲願構廠鹽餘餘構築鑰遞齋齋 (鑰艱鹹繭廠餘醖艱膚築, 0.010 ~ 0.051) 更多